Compare · BCTX vs NVO
BCTX vs NVO
Side-by-side comparison of BriaCell Therapeutics Corp. (BCTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 5301.9x BCTX ($32.8M).
- Over the past year, BCTX is down 70.8% and NVO is down 28.6% - NVO leads by 42.3 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for BCTX).
- NVO has more recent analyst coverage (25 ratings vs 1 for BCTX).
- Company
- BriaCell Therapeutics Corp.
- Novo Nordisk A/S
- Price
- $3.43-8.90%
- $38.82-1.05%
- Market cap
- $32.8M
- $173.66B
- 1M return
- -19.86%
- -10.14%
- 1Y return
- -70.83%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 4
- Recent ratings
- 1
- 25
BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BCTX
- BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
- Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
- Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs
- BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
- BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
- BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
- BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
- BriaCell Therapeutics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
- SEC Form 10-Q filed by BriaCell Therapeutics Corp.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank